[go: up one dir, main page]

PT2489733T - Terapia genética para esclerose lateral amiotrófica e outros distúrbios da medula espinal - Google Patents

Terapia genética para esclerose lateral amiotrófica e outros distúrbios da medula espinal

Info

Publication number
PT2489733T
PT2489733T PT12152550T PT12152550T PT2489733T PT 2489733 T PT2489733 T PT 2489733T PT 12152550 T PT12152550 T PT 12152550T PT 12152550 T PT12152550 T PT 12152550T PT 2489733 T PT2489733 T PT 2489733T
Authority
PT
Portugal
Prior art keywords
gene therapy
spinal cord
lateral sclerosis
amyotrophic lateral
cord disorders
Prior art date
Application number
PT12152550T
Other languages
English (en)
Inventor
Shihabuddin Lamya
R O'riordan Catherine
Dodge James
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PT2489733T publication Critical patent/PT2489733T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT12152550T 2006-06-07 2007-06-07 Terapia genética para esclerose lateral amiotrófica e outros distúrbios da medula espinal PT2489733T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81141906P 2006-06-07 2006-06-07

Publications (1)

Publication Number Publication Date
PT2489733T true PT2489733T (pt) 2019-05-27

Family

ID=38832369

Family Applications (2)

Application Number Title Priority Date Filing Date
PT12152550T PT2489733T (pt) 2006-06-07 2007-06-07 Terapia genética para esclerose lateral amiotrófica e outros distúrbios da medula espinal
PT77958353T PT2029742T (pt) 2006-06-07 2007-06-07 Terapia genética para esclerose lateral amiotrófica e outros transtornos da medula espinal

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT77958353T PT2029742T (pt) 2006-06-07 2007-06-07 Terapia genética para esclerose lateral amiotrófica e outros transtornos da medula espinal

Country Status (19)

Country Link
US (4) US9034836B2 (pt)
EP (3) EP3540054A3 (pt)
JP (6) JP2009539847A (pt)
CN (1) CN101460621B (pt)
AR (2) AR061282A1 (pt)
BR (1) BRPI0711965A2 (pt)
CA (2) CA3139726A1 (pt)
CY (1) CY1118555T1 (pt)
ES (2) ES2725552T3 (pt)
HU (2) HUE044182T2 (pt)
IL (2) IL195647A (pt)
LT (2) LT2489733T (pt)
MX (4) MX2008015530A (pt)
PL (2) PL2029742T3 (pt)
PT (2) PT2489733T (pt)
RU (1) RU2008152821A (pt)
SI (2) SI2489733T1 (pt)
TR (1) TR201906106T4 (pt)
WO (1) WO2007146046A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061282A1 (es) 2006-06-07 2008-08-20 Genzyme Corp Terapia genica para esclerosis lateral amiotrofica y otros trastornos del cordon espinal
WO2009089635A1 (en) * 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
CN102272321A (zh) 2008-10-31 2011-12-07 神经动力公司 神经毒性甾醇糖苷
CN107083400A (zh) 2009-05-02 2017-08-22 建新公司 神经退行性疾病的基因治疗
CA2818253A1 (en) * 2010-11-16 2012-05-24 Denis G. Kay Method for increasing neprilysin expression and activity
CN103083667A (zh) * 2011-11-01 2013-05-08 北京清美联创干细胞科技有限公司 嗅鞘细胞增殖试剂的连续给药方案
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
IN2015KN00329A (pt) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
US20140065110A1 (en) * 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
CA2889499C (en) 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
WO2014084085A1 (ja) * 2012-11-28 2014-06-05 国立大学法人名古屋大学 聴覚障害又は小脳性運動失調症の予防・治療剤
MX2015015244A (es) * 2013-05-01 2016-07-05 Genzyme Corp Composiciones y metodos para tratar la atrofia muscular espinal.
KR20220106852A (ko) * 2013-07-26 2022-07-29 유니버시티 오브 아이오와 리써치 파운데이션 뇌 질환을 치료하기 위한 방법 및 조성물
KR101548989B1 (ko) 2013-07-30 2015-09-01 광주과학기술원 ＳｉｒＴ１을 이용한 관절 질환의 예방 또는 치료용 물질의 스크리닝 방법
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
DE102014207498A1 (de) * 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
US10335466B2 (en) 2014-11-05 2019-07-02 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of parkinson's disease
MX2017014966A (es) * 2015-05-28 2018-08-15 Univ Cornell Liberación de c1ei mediada por virus adenoasociado como terapia para el angioedema.
CL2015003024A1 (es) 2015-10-09 2016-05-13 Univ Chile Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrofica.
US10357543B2 (en) 2015-11-16 2019-07-23 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein
CA3016314A1 (en) * 2016-03-02 2017-09-08 Julianne REIDERS Therapy for frontotemporal dementia
PT3589730T (pt) 2017-02-28 2024-02-28 Univ Pennsylvania Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
EP3692151A4 (en) 2017-10-03 2021-07-14 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISORDERS
KR102693318B1 (ko) 2017-10-03 2024-08-07 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
KR102709597B1 (ko) * 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
CN111405911A (zh) * 2017-10-10 2020-07-10 梅迪塞纳医疗股份有限公司 用于治疗中枢神经系统(cns)肿瘤的il-4融合制剂
RU2731514C2 (ru) * 2018-12-21 2020-09-03 Селл энд Джин Терапи Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов SHH, CTNNB1, NOG, WNT7A для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-SHH, или Escherichia coli SCS110-AF/VTvaf17-CTNNB1, или Escherichia coli SCS110-AF/VTvaf17-NOG, или Escherichia coli SCS110-AF/VTvaf17-WNT7A, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
MA54874A (fr) * 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement des troubles neurocognitifs
KR20210131370A (ko) * 2019-02-22 2021-11-02 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스
JP7571044B2 (ja) 2019-04-10 2024-10-22 プリベイル セラピューティクス，インコーポレーテッド リソソーム障害のための遺伝子療法
MX2021012527A (es) * 2019-04-12 2022-01-06 Encoded Therapeutics Inc Composiciones y métodos de administración de terapéuticos.
CN113660958B (zh) * 2019-10-12 2023-10-31 深圳大学 使Sirt7基因表达的作用剂及其用途
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
CN115323002A (zh) * 2022-07-28 2022-11-11 深圳先进技术研究院 一种基因递送系统在从脑部逆行递送基因到脊髓神经元中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
CA2173975C (en) 1993-10-25 2007-06-12 Richard J. Gregory Recombinant adenoviral vector and methods of use
JPH09509564A (ja) 1993-11-09 1997-09-30 ターゲテッド ジェネティックス コーポレイション 高力価組換えａａｖベクターの生成
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ATE386131T1 (de) 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
WO1997039789A1 (en) 1996-04-22 1997-10-30 Medtronic, Inc. Two-stage angled venous cannula
US20040076613A1 (en) * 2000-11-03 2004-04-22 Nicholas Mazarakis Vector system
EP1034267A1 (en) 1997-12-04 2000-09-13 Genzyme Corporation Compositions and methods for inducing gene expression
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US7037493B2 (en) * 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
ES2327609T3 (es) * 2000-06-01 2009-11-02 University Of North Carolina At Chapel Hill Procedimientos y compuestos para controlar la liberacion de vectores de parvovirus reconbinantes.
EP1319082B1 (en) 2000-09-18 2005-11-16 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
GB0103998D0 (en) * 2001-02-19 2001-04-04 King S College London Method
JP2002322068A (ja) * 2001-02-26 2002-11-08 Japan Science & Technology Corp 血管再生促進剤
WO2003004660A1 (en) * 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
EP1478236B1 (en) 2001-12-21 2009-02-11 The Salk Institute For Biological Studies Targeted retrograde gene delivery to motor neurons
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AU2003215297A1 (en) * 2002-02-15 2003-09-09 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
AU2003268484A1 (en) * 2002-09-06 2004-03-29 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
US7803920B2 (en) 2004-09-29 2010-09-28 Shinya Yamanaka ECAT16 gene expressed specifically in ES cells and utilization of the same
WO2006054600A1 (ja) * 2004-11-18 2006-05-26 Tokyo Medical And Dental University 新規タンパク質及びそれを利用したポリグルタミン病等の神経変性疾患の予防・治療薬
WO2006119341A2 (en) * 2005-05-02 2006-11-09 Genzyme Corporation Gene therapy for spinal cord disorders
ES2887076T3 (es) 2005-05-02 2021-12-21 Genzyme Corp Terapia génica para trastornos neurometabólicos
AR061282A1 (es) 2006-06-07 2008-08-20 Genzyme Corp Terapia genica para esclerosis lateral amiotrofica y otros trastornos del cordon espinal
ES2745471T3 (es) 2011-11-01 2020-03-02 Resverlogix Corp Formulaciones orales de liberación inmediata para quinazolinonas sustituidas
EP2864488A1 (en) 2012-06-21 2015-04-29 Association Institut de Myologie Widespread gene delivery of gene therapy vectors

Also Published As

Publication number Publication date
US20230364200A1 (en) 2023-11-16
HUE044182T2 (hu) 2019-10-28
CN101460621A (zh) 2009-06-17
US9034836B2 (en) 2015-05-19
ES2725552T3 (es) 2019-09-24
LT2489733T (lt) 2019-05-27
CN101460621B (zh) 2016-01-27
EP2489733A2 (en) 2012-08-22
WO2007146046A3 (en) 2008-05-22
PT2029742T (pt) 2016-09-09
CA3139726A1 (en) 2007-12-21
CY1118555T1 (el) 2017-07-12
PL2489733T3 (pl) 2019-08-30
SI2029742T1 (sl) 2016-11-30
JP6320489B2 (ja) 2018-05-09
IL241890A0 (en) 2015-11-30
PL2029742T3 (pl) 2017-08-31
US20160067312A1 (en) 2016-03-10
MX2008015530A (es) 2009-02-06
TR201906106T4 (tr) 2019-05-21
EP2029742A2 (en) 2009-03-04
IL195647A0 (en) 2009-09-01
JP2020079234A (ja) 2020-05-28
JP2009539847A (ja) 2009-11-19
JP2015120719A (ja) 2015-07-02
MX2023001965A (es) 2023-02-23
US20100267812A1 (en) 2010-10-21
EP2489733A3 (en) 2012-11-14
JP2017078071A (ja) 2017-04-27
JP2018118995A (ja) 2018-08-02
JP6606215B2 (ja) 2019-11-13
AR109171A2 (es) 2018-11-07
JP2014012697A (ja) 2014-01-23
EP3540054A2 (en) 2019-09-18
RU2008152821A (ru) 2010-07-20
US20200101138A1 (en) 2020-04-02
MX364444B (es) 2019-04-26
EP2029742A4 (en) 2009-09-30
LT2029742T (lt) 2016-11-10
BRPI0711965A2 (pt) 2012-01-24
EP3540054A3 (en) 2019-10-09
US11554161B2 (en) 2023-01-17
CA2654292A1 (en) 2007-12-21
IL195647A (en) 2015-10-29
AR061282A1 (es) 2008-08-20
SI2489733T1 (sl) 2019-06-28
MX2019004843A (es) 2021-06-15
CA2654292C (en) 2022-01-11
ES2596885T3 (es) 2017-01-12
HUE031156T2 (en) 2017-06-28
WO2007146046A2 (en) 2007-12-21
EP2489733B1 (en) 2019-02-13
EP2029742B1 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
PL2489733T3 (pl) Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego
PT3146982T (pt) Terapia génica para esclerose lateral amiotrófica e outros distúrbios da medula espinal
IL237658A0 (en) Gene therapy for spinal cord disorders
HRP20182147T8 (hr) Novi terapijski pristupi za liječenje cmt-a i srodnih poremećaja
EP2010187A4 (en) CONNECTIONS FOR DISEASES AND FUNCTIONAL DISORDERS
IL198492A0 (en) Pathotropic targeted gene delivery system for cancer and other disorders
HK1205530A1 (en) Gene expression and pain
PL1993589T3 (pl) Sposoby leczenia chorób neurologicznych
IL193697A0 (en) Methods for treating cognitive and other disorders
EP2099389A4 (en) IMPLANTABLE INTERVERTEBRAL DISC
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
SI1879623T1 (sl) Genska terapija za motnje hrbtenjače
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
IL255035A0 (en) Gene therapy for spinal cord disorders
GB0616452D0 (en) Novel therapy for joint disorders
AU2006901311A0 (en) Liver-directed gene therapy
SI1993589T1 (sl) Zdravljenje za nevrološka obolenja